Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Bone Metastases in Subjects With Advanced Breast Cancer Clinical Trial

Official title:
A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates

Status Completed

Clinical Trial Summary

The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00104650
Study type	Interventional
Source	Amgen
Contact
Status	Completed
Phase	Phase 2
Start date	January 2005
Completion date	March 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00091832` - Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer	Phase 2
Completed	`NCT01419717` - Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer	Phase 3
Completed	`NCT00950911` - Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only	Phase 3